Simulect 20 mg, Pulver zur Herstellung einer Injektions-/Infusionslösung - Swissmedic Key 69542001 Registration Holder Novartis Pharma Schweiz AG Name Simulect 20 mg, Pulver zur Herstellung einer Injektions-/Infusionslösung Date of registration 26.10.2023 Introduction of Sequence 26.10.2023 ATC-Classification Basiliximab (L04AC02) Revision date WHO WHO-DDD Valid until 25.10.2028 Index Therapeuticus (BSV) Show package size Index Therapeuticus (Swissmedic) 07.15. Description Swissmedic categorie. B SL Eintrag No Indication Information for professionals IP Consumer information Ex-factory-Price PR Deductible k.A. Consumer price PR Feedback FB GTIN 7680695420012 Medication Code Biotechnologika Pharmacode Disponibility
Composition basiliximabum 20 mg, mannitolum, glycinum, saccharum, dinatrii phosphas, kalii dihydrogenophosphas, natrii chloridum, pro vitro corresp. natrium 0.955 mg. Packungsbestandteile Galenic Form Dry substance Excipiens Active Agent Dose Basiliximab 20 mg
Inactive agents Disodium Phosphate Glycin Potassium Dihydrogenophosphate Mannitol Sodium Chloride Saccharum
Source Data was imported : 08.11.2023
Swissmedic Registration :
Sequence :
Product name :
Registration owner: :
Product group :
Index Therapeuticus (BSV) :
Medication Code :
Date of registration :
Valid until :
Package number :
Show package size :
Commercial Form/Unit :
Swissmedic categorie. :
Active Agents :
Composition :
